Star Diamond
TSE:DIAMStar Diamond Corporation engages in the exploration, development, and production of diamonds in Canada. The company's principal mineral properties include the Star Kimberlite property and the Orion South Kimberlite property located in Fort à la Corne area of Saskatchewan, Canada. It also holds a 50% interest in the Buffalo Hills project located in north central Alberta, Canada. The company was formerly known as Shore Gold Inc. and changed its name to Star Diamond Corporation in February 2018. Star Diamond Corporation was incorporated in 1985 and is headquartered in Saskatoon, Canada.
LeadFX
TSE:LFXLeadFX Inc., a mining company, focuses on the development of lead-silver projects. Its principal asset is the Paroo Station mine, a restart-ready lead carbonate mine, located in Western Australia. The company was formerly known as Ivernia Inc. and changed its name to LeadFX Inc. in October 2015. The company is headquartered in Burswood, Australia. LeadFX Inc. is a subsidiary of Sentient Group of Global Resource Funds.
Cassiar Gold Corp. (MRL.V)
CVE:MRLMargaux Resources Ltd., a polymetallic exploration company, engages in the acquisition, exploration, and development of mineral properties in the Kootenay Arc in Southeastern British Columbia in Canada. The company primarily explores for zinc, gold, and tungsten deposits. It holds an option agreement to acquire a 100% interest in the Jackpot/Oxide, Ore Hill, Aspenex, Bayonne, Sheep Creek, Canex, and Old Timer properties located in Salmo, British Columbia. The company was formerly known as Carmen Energy Inc. and changed its name to Margaux Resources Ltd. in July 2013. Margaux Resources Ltd. was incorporated in 2009 and is based in Calgary, Canada.
Mylan
NASDAQ:MYLMylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.